How to Ensure Your Treatment is Aimed at the Bull's Eye

As with any big decision in life, you cannot be too careful, and this is very much the case with your targeted therapy. There is often more than one target in a tumor, and a treatment strategy is to guess the driver-gene target that will result in a successful treatment. If the chosen gene target is found not to be the driver gene of the tumor, then another target needs to be guessed to bring the tumor under control. This guesswork process continues until the correct driver gene is chosen as the target. This process is both inefficient and expensive. Cancer genomic profiling enables major targets to be revealed all at once, such as EGFR, ALK, ROS1, etc, and then by identifying the driver gene, you will be aiming at the bull's eye and increase the chances of having a successful treatment.

‍

Common Problems in Cancer Treatment

• Chemotherapy and surgery are the only options recommended by the NCCN guidelines or single-gene testing results
• Complications and metastases make it difficult to determine an appropriate drug
• Ineffective treatment and cancer relapse after targeted therapy

Diagnostic Solutions for Various Cancers

Through next-generation sequencing (NGS), ACTDrug^®+ targeted genomic profiling decodes 40 cancer genes to map drug options based on thorough clinical research, is not limited to a single clinical treatment guideline and determines the growth mechanism on a genomic level to provide more treatment strategy options with a higher success rate. ACTDrug^®+ is suitable for breast, lung, colon cancers and other solid tumors. As single gene testing only provides very limited results, NGS genomic profiling can detect any special genomic mutations to result in a more effective treatment; if recurrence or metastases are found, treatment can be modified according to the NGS genomic profiling result to overcome drug resistance.

Who Is Suitable for ACTDrug®+?

• All solid tumor patients including common cancer and rare cancer